Thursday, 2 October 2014

The future of ASPREE

Investigators to the ASPREE study and sub-studies with the ASPREE management team
Australian investigators recapped the progress and future of the ASPREE study, ASPREE ancillary studies and the STAREE trial during a one and half day meet last week.


ASPREE (ASPirin in Reducing Events in the Elderly) has almost reached its recruitment target of 19,000 participants in Australia and the US.

The trial has 11 sub-studies investigating the effect of aspirin on: osteoarthritis (ASPREE-Knee), osteoporosis (ASPREE- FALLS & FRACTURES), age-related macular degeneration (ASPREE-AMD), sleep apnoea (SNORE-ASA), infection (ASPREE-ANTISEPSIS), cancer (ACES – ASPREE Cancer Endpoints Study), hearing loss (ASPREE-HEARING), microvascular changes in the brain (ASPREE-NEURO) and whether microvascular changes in the brain are reflected in the retina (ENVIS-ion). ALSOP (ASPREE Longitudinal Study in Older Persons) questionnaires identify medical and social factors that may affect the ability to age well, while the ASPREE Healthy Ageing Biobank will help identify biological indicators of disease that may develop in later years or even good health.

STAREE (STAtins in Reducing Events in the Elderly), the first randomised controlled trial of statin therapy in healthy older people, aims to commence recruitment early next year.

No comments:

Post a Comment

linkwithin

Related Posts Plugin for WordPress, Blogger...